Creating a free account will enable you to subscribe to our daily and weekly email newsletters, as well as customize your reading experience to show only the categories most relevant to you.
Signing up only take a few minutes, so why not give it a try and see what you've been missing out on.
Continued use of statins may help prevent delirium in critically ill patients who received statins before hospital admission, according to a new study of 470 intensive care patients in the UK.
"This is the first study using a validated delirium screening tool, the Confusion Assessment Method-ICU (CAM-ICU), to show that the administration of statins reduces delirium in these patients," said lead author Valerie J Page MB ChB, of the Watford General Hospital in Watford, UK. "This benefit may be mediated by a reduction in systemic inflammation."
The findings were published online ahead of print publication in the American Thoracic Society's American Journal of Respiratory and Critical Care Medicine.
Of the 470 patients included in the study, 151 received statins. Statins were only administered to patients who had received statins prior to admission.
After adjustment for age, sex and illness severity, administration of statins the previous evening was associated with a significantly lower risk of delirium and a concomitant reduction in serum C-reactive protein (CRP), a marker of systemic inflammation, the following day. The strength of the relationship between statin use and a lower risk of delirium was reduced when CRP was adjusted for.
"Although the pathogenesis of delirium is not fully understood, these data are consistent with a neuro-inflammatory cause and suggest that the anti-inflammatory effects of statins may contribute to the effects of statin treatment on delirium," said Dr. Page. "Our study on statin use and the risk of delirium in critically ill subjects included extensive data on a large, broadly representative population of consecutive intensive care patients, increasing its strength."
Study limitations include the possibility that not all potential confounding factors were adjusted for and the limits of cognitive assessment tools in critically ill patients.
"Our findings suggest that statin treatment should be continued to help prevent delirium in critically ill patients who received statins before being admitted," said Dr. Page.
"The relationship between statin therapy and delirium and the mechanisms underlying this relationship are the subject of an ongoing randomized, placebo-controlled study in critically ill ventilated patients."
Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our Statins category page for the latest news on this subject.
Please use one of the following formats to cite this article in your essay, paper or report:
American Thoracic Society. "Continuing statins in critically ill patients reduces delirium." Medical News Today. MediLexicon, Intl., 21 Jan. 2014. Web.
9 Mar. 2014. <http://www.medicalnewstoday.com/releases/271414>
American Thoracic Society. (2014, January 21). "Continuing statins in critically ill patients reduces delirium." Medical News Today. Retrieved from
Please note: If no author information is provided, the source is cited instead.
If you write about specific medications, operations, or procedures please do not name healthcare professionals by name.
For any corrections of factual information, or to contact our editorial team, please use our feedback form. Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
This page was printed from: http://www.medicalnewstoday.com/releases/271414.php
Visit www.medicalnewstoday.com for medical news and health news headlines posted throughout the day, every day.
© 2004-2014 All rights reserved. MNT (logo) is the registered trade mark of MediLexicon International Limited.